Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;76(1):114-130.
doi: 10.1111/all.14295.

Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

Milena Sokolowska  1   2 , G Enrico Rovati  3 , Zuzana Diamant  4   5 , Eva Untersmayr  6 , Jargen Schwarze  7 , Zuzanna Lukasik  1 , Florentina Sava  8 , Alba Angelina  9 , Oscar Palomares  9 , Cezmi A Akdis  1   2 , Liam O'Mahony  10 , Marek Sanak  11 , Sven-Erik Dahlen  12   13 , Grzegorz Woszczek  14
Affiliations
Review

Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I

Milena Sokolowska et al. Allergy. 2021 Jan.

Abstract

Eicosanoids are biologically active lipid mediators, comprising prostaglandins, leukotrienes, thromboxanes, and lipoxins, involved in several pathophysiological processes relevant to asthma, allergies, and allied diseases. Prostaglandins and leukotrienes are the most studied eicosanoids and established inducers of airway pathophysiology including bronchoconstriction and airway inflammation. Drugs inhibiting the synthesis of lipid mediators or their effects, such as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently prostaglandin D2 receptor antagonists, have been shown to modulate features of asthma and allergic diseases. This review, produced by an European Academy of Allergy and Clinical Immunology (EAACI) task force, highlights our current understanding of eicosanoid biology and its role in mediating human pathology, with a focus on new findings relevant for clinical practice, development of novel therapeutics, and future research opportunities.

Keywords: asthma; food allergy; inflammation; leukotrienes; lipid mediators; prostaglandins; rhinitis.

PubMed Disclaimer

References

    1. Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997;17:3S-12S.
    1. Samuchiwal SK, Boyce JA. Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology. J Allergy Clin Immunol. 2018;141:1182-1190.
    1. Diamant Z, Aalders W, Parulekar A, Bjermer L, Hanania NA. Targeting lipid mediators in asthma: time for reappraisal. Curr Opin Pulm Med. 2019;25:121-127.
    1. Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol. 2009;5:639-658.
    1. Le HD, Meisel JA, de Meijer VE, Gura KM, Puder M. The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids. 2009;81:165-170.

Publication types

LinkOut - more resources